Breaking News Instant updates and real-time market news.

IMMY

Imprimis

$3.36

0.28 (9.09%)

, VRX

Valeant

$22.18

-0.59 (-2.59%)

08:34
10/17/16
10/17
08:34
10/17/16
08:34

Imprimis announces availability of lower-cost option for lead poison treatment

Imprimis Pharmaceuticals (IMMY) announced the availability of a significantly lower-cost compounded alternative to Valeant's (VRX) Calcium Disodium Versenate, commonly used to stabilize and treat patients exposed to lead poisoning. Imprimis' compounded EDTA calcium disodium injection is priced at $495 for a five-day treatment. According to the World Health Organization, dosing for this drug is based on blood lead levels and body surface area and can range from 1000mg to 2000mg or more daily for five days of treatment. Using Valeant's product, the estimated cost of therapy would be $27,000 for a five-day treatment. Valeant has increased the price of Calcium Disodium Versenate by over 2,700% since it acquired the drug as part of its purchase of Medicis in 2013. The original cost was $950 and it increased under Valeant's control to $7,116 in early 2014, with additional increases the same year to its current price of $27,000.

IMMY

Imprimis

$3.36

0.28 (9.09%)

VRX

Valeant

$22.18

-0.59 (-2.59%)

  • 16

    Nov

  • 14

    Dec

IMMY Imprimis
$3.36

0.28 (9.09%)

02/23/16
JMPS
02/23/16
NO CHANGE
JMPS
Retrophin well-positioned to defend Thiola franchise, says JMP Securities
After conducting checks, JMP Securities says that Retrophin is well-positioned to defend its Thiola franchise against the much cheaper, compounded version that Imprimis Pharmaceuticals (IMMY) plans to launch in April. The firm says its feedback form one expert suggests that doctors will resist using a compounded version of the product due to the risks associated with compound pharmacies, lack of issues with accessing Thiola and the ability to measure the main ingredients in Thiola. JMP keeps a $28 price target and Outperform rating on the shares.
VRX Valeant
$22.18

-0.59 (-2.59%)

10/14/16
WELS
10/14/16
NO CHANGE
WELS
Underperform
Wells says Valeant price hikes a reaction to 'disappointing' prescription trends
Wells Fargo analyst David Maris noted Valeant's announcement earlier today that the company has decided to raise prices by 2% to 9% on a broad range of products. He believes the price increases are a result of the company taking "a sobering look at disappointing prescription trends" and continues to contend that consensus estimates for Valeant in 2017 are too high. The analyst, who has kept an Underperform rating on Valeant shares since starting coverage of the stock in February, said the company's "story is the same as it has been, and the only change is in how it is being told."
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.

TODAY'S FREE FLY STORIES

EQGP

EQT GP

$26.75

-0.39 (-1.44%)

06:52
04/27/17
04/27
06:52
04/27/17
06:52
Hot Stocks
EQT GP increases quarterly distribution 8% to 19.1c per share »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    May

POL

PolyOne

$37.39

-0.02 (-0.05%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
PolyOne reports Q1 adjusted EPS 59c, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
Extended Stay America reports Q1 adj. EPS 15c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

, GOOG

Alphabet

$871.73

-0.57 (-0.07%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Periodicals
Fiat Chrysler seeks more self-driving supplier partners, Reuters reports »

Fiat Chrysler (FCAU) is…

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

GOOG

Alphabet

$871.73

-0.57 (-0.07%)

GOOGL

Alphabet Class A

$889.14

0.3 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
Nintendo reports FY16 profit per share Y853.87 vs. Y137.4 last year »

Reports FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:50
04/27/17
04/27
06:50
04/27/17
06:50
General news
Front-month WTI crude prices are down 1% »

Front-month WTI crude…

EXAS

Exact Sciences

$23.80

-1.09 (-4.38%)

06:50
04/27/17
04/27
06:50
04/27/17
06:50
Technical Analysis
Exact Sciences hits new 52-week high after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 30

    May

  • 06

    Jun

BWA

BorgWarner

$41.06

0.22 (0.54%)

06:49
04/27/17
04/27
06:49
04/27/17
06:49
Earnings
BorgWarner now sees FY17 EPS $3.50-$3.60, consensus $3.41 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

SDPI

Superior Drilling

$0.79

-0.0099 (-1.24%)

06:49
04/27/17
04/27
06:49
04/27/17
06:49
Earnings
Breaking Earnings news story on Superior Drilling »

Superior Drilling sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOW

Dow Chemical

$64.33

-0.48 (-0.74%)

06:48
04/27/17
04/27
06:48
04/27/17
06:48
Hot Stocks
Breaking Hot Stocks news story on Dow Chemical »

Dow Chemical reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

  • 11

    May

DOW

Dow Chemical

$64.33

-0.48 (-0.74%)

06:48
04/27/17
04/27
06:48
04/27/17
06:48
Hot Stocks
Dow Chemical reports Q1 EBITDA $2.1B »

Q1 operating EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

  • 11

    May

BWA

BorgWarner

$41.06

0.22 (0.54%)

06:47
04/27/17
04/27
06:47
04/27/17
06:47
Earnings
BorgWarner sees Q2 EPS 87c-91c, consensus 87c »

Sees Q2 organic net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

RHHBY

Roche

$32.20

-0.207 (-0.64%)

06:47
04/27/17
04/27
06:47
04/27/17
06:47
Hot Stocks
Roche CEO Severin Schwan says 'well on track' to meet full-year targets »

Commenting on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 06

    Jun

  • 26

    Jun

RHHBY

Roche

$32.20

-0.207 (-0.64%)

06:46
04/27/17
04/27
06:46
04/27/17
06:46
Earnings
Roche reports Q1 group sales CHF12.94B vs. CHF12.41B last year »

Group sales increased 4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 06

    Jun

  • 26

    Jun

BWA

BorgWarner

$41.06

0.22 (0.54%)

06:46
04/27/17
04/27
06:46
04/27/17
06:46
Earnings
BorgWarner reports Q1 EPS 89c, consensus 84c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

XRF

China Rapid Finance

06:45
04/27/17
04/27
06:45
04/27/17
06:45
Syndicate
China Rapid Finance 10M share IPO price range lowered to $6.00-$7.00 »

China Rapid Finance 10M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

DOW

Dow Chemical

$64.33

-0.48 (-0.74%)

06:45
04/27/17
04/27
06:45
04/27/17
06:45
Earnings
Dow Chemical reports Q1 operating EPS $1.04, consensus 98c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

  • 11

    May

HP

Helmerich & Payne

$65.21

-0.18 (-0.28%)

06:45
04/27/17
04/27
06:45
04/27/17
06:45
Earnings
Helmerich & Payne reports Q2 EPS (45c) with items, consensus (40c) »

Reports Q2 revenue $405M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

RHHBY

Roche

$32.20

-0.207 (-0.64%)

06:44
04/27/17
04/27
06:44
04/27/17
06:44
Hot Stocks
Roche confirms FY17 outlook, sees sales up low to mid single digits »

In 2017, Roche expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 06

    Jun

  • 26

    Jun

BSX

Boston Scientific

$25.97

0.23 (0.89%)

06:44
04/27/17
04/27
06:44
04/27/17
06:44
Earnings
Boston Scientific baks FY17 adj. EPS view of $1.22-$1.26, consensus $1.25 »

Raises FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 07

    Jun

  • 27

    Jun

AKAM

Akamai

$62.24

0.44 (0.71%)

06:43
04/27/17
04/27
06:43
04/27/17
06:43
Downgrade
Akamai rating change  »

Akamai downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 08

    Jun

  • 15

    Jun

CSCO

Cisco

$33.40

-0.02 (-0.06%)

, SPLK

Splunk

$63.72

-0.13 (-0.20%)

06:43
04/27/17
04/27
06:43
04/27/17
06:43
Upgrade
Credit Suisse double upgrades Cisco on possible M&A transformation »

Cisco Systems'…

CSCO

Cisco

$33.40

-0.02 (-0.06%)

SPLK

Splunk

$63.72

-0.13 (-0.20%)

NOW

ServiceNow

$90.92

0.68 (0.75%)

PANW

Palo Alto Networks

$109.27

-1.13 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 12

    Jun

WCC

WESCO

$68.00

0.6 (0.89%)

06:42
04/27/17
04/27
06:42
04/27/17
06:42
Earnings
WESCO sees Q2 sales down 2% to up 1%, consensus $1.92B »

Sees Q2 operating margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

  • 07

    Jun

WCC

WESCO

$68.00

0.6 (0.89%)

06:42
04/27/17
04/27
06:42
04/27/17
06:42
Earnings
WESCO backs FY17 EPS $3.60-$4.00, consensus $3.87 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

  • 07

    Jun

BSX

Boston Scientific

$25.97

0.23 (0.89%)

06:42
04/27/17
04/27
06:42
04/27/17
06:42
Earnings
Boston Scientific reports Q1 adj. EPS 29c, consensus 30c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 07

    Jun

  • 27

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.